Minted: - / 5000

297 Zuranolone
cfeb0af4aadb7aac668f0a0a674453c1d8bd3a0825cb4ecbad32bf863ba9de75

Properties

Background

Blue
Bottle

Orange
Cap

Purple
Syringe

Purple
Bubbles
No
Drops
No
Label
Drop

Chemistry

Formula
C25H35N3O2
Carbon
25
Polarity
Neutral

Zuranolone (; developmental code names SAGE-217, S-812217) is an investigational medication which is under development by SAGE Therapeutics for the treatment of depressive disorders and a variety of other indications. It is a synthetic, orally active, inhibitory pregnane neurosteroid, and acts as a positive allosteric modulator of the GABA_A receptor. The drug was developed as an improvement of allopregnanolone (brexanolone) with high oral bioavailability and a biological half-life suitable for once-daily administration. As of October 2019, zuranolone is in phase III clinical trials for major depressive disorder, postpartum depression, and insomnia and is in phase II clinical studies for bipolar depression, essential tremor, and Parkinson's disease. It is also in the preclinical stage of development for dyskinesias.

From Wikipedia, the free encyclopedia. License: CC BY-SA.